Marizyme, Inc. Stock Price - MRZM

Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Canna Trader Pro
Monthly Subscription
for only
$59.99
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Marizyme, Inc. MRZM OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.82 0.00 0.00 0.00 0.82 14:41:56
Bid Price Ask Price Spread Spread % News
0.60 0.87 0.27 31.03% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Marizyme, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 16.28M 19.86M $ -248.74k - - 2.52M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
105.00 $ - 0.00% - -

more financials information »

Marizyme, Inc. News

Loading Messages....

Latest MRZM Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MRZM Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.820.820.820.821,0000.000.0%
1 Month1.051.100.400.54971911,424-0.23-21.9%
3 Months1.001.960.400.8854803704-0.18-18.0%
6 Months1.971.980.31060.8470207830-1.15-58.38%
1 Year1.412.100.31061.301,443-0.59-41.84%
3 Years0.063.400.0150.112659631,8470.761,266.67%
5 Years0.1653.400.0150.109564127,3280.655396.97%

Marizyme, Inc. Description

We are a biotechnology company with clinically tested and patented use of protease therapeutic platform for the treatment of acute ischemic stroke, acute myocardial infactions, deep vein thrombosis and chronic wounds and burns. We call our platform Krillase®. We are focused on bringing late stage biopharmaceutical products to market in the acute care space that have been undervalued or need experienced leadership to successfully commercialize. We expect to reduce investor risk by diversifying our product portfolio with late stage highly de-risked assets with competitive advantages in safety, efficacy, cost and ease of use. This approach will allow us to grow through multiple applications and drive value through diversity.


Your Recent History
USOTC
MRZM
Marizyme, ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.